



qB

IFW 1616\$

Patent Application
Attorney Docket No. PC8835E

I hereby certify that this correspondence is being deposited with the United States Postal Service as **first-class mail** in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 10th day of February 2006.

By

Madeline Deveran

(Signature of person mailing)

Madeline Deveran

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:
Kimberly O. Cameron et al.

Examiner: Nathaniel Alton Pryor

APPLICATION NO.: 09/820,158

Group Art Unit: 1616

FILING DATE: March 28, 2001

TITLE: **ESTROGEN AGONISTS/ANTAGONISTS FOR
PREVENTING BREAST CANCER**

Mail Stop: Amendment
Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the reference(s) cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

You are hereby authorized to charge the fee due under 37 C.F.R. 1.17(p) and other applicable fees to deposit account number 16-1445.


02/15/2006 MAHMED1 00000014 161445 09820158

01 FC:1806 180.00 DA

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 10 FEBRUARY 2006
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-6645


John A. Wichtowski
Attorney for Applicant(s)
Reg. No. 48,032



SUPPLEMENTAL INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC8835E			SERIAL NO. 09/820,158					
										APPLICANT Kimberly O. Cameron, et al.								
										FILING DATE March 28, 2001			GROUP 1616					
U.S. PATENT DOCUMENTS																		
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
	US	3	8	7	5	2	4	2	4/1/75	D. Lednicer Equivalent FR1580534	260	613						
FOREIGN PATENT DOCUMENTS																		
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION					
													YES	NO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																		
		Chemical Abstracts, Vol. 64, pp. 15811-15814, 1966																
		Chemical Abstracts, Vol. 65, No. 3, Abstract 5425b 1966																
		Chemical Abstracts, Vol. 66, Abstract 46256d, 1967																
		Chemical Abstracts, Vol. 73, Abstract 76943n, 1970																
		Hutchens, et al., <u>Molecular Endocrinology</u> , "Unique Molecular Properties of a Urea- and Salt-Stable DNA-Binding Estrogen Receptor Dimmer Covalently Labeled With The Antiestrogen [³ H] Desmethylnafodine Aziridine.", pp. 255-267, (1990)																
		Katzenellenbogen, et al., <u>Hormones and Cancer</u> , "Antiestrogen Action In Estrogen Target Tissues: Receptor Interactions And Antiestrogen Metabolism", pp. 309-320, (1980)																
		Katzenellenbogen, et al., <u>Journal of Steroid Biochemistry</u> , "Antiestrogen Pharmacology and Mechanism of Action", Vol. 19, pp. 59-68, (1983)																
		Leclercq, et al., <u>Journal of Steroid Biochemistry</u> , "Guide-Lines In The Design Of New Antiestrogens And Cytotoxic-Linked Estrogens For The Treatment Of Breast Cancer", Vol. 19, pp. 75-85, (1983)																
		Tatee, et al., <u>Journal of Medicinal Chemistry</u> , "Antiestrogens and Antiestrogen Metabolites: Preparation of Tritium-Labeled (±)-cis-3-[p-(1,2,3,4-Tetrahydro-6-methoxy-2-phenyl-1-naphthyl) phenoxy]-1,2-propanediol (U-23469) and Characterization and Sythesis of a Biologically Important Metabolite", Vol. 22, pp. 1509-1517, (1979)																
EXAMINER																		
DATE CONSIDERED																		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																		